Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases

Su, Guanyue; Gao, Feng; Yang, Mengzhao; Wang, Ling; Liang, Lili; Li, Silin; Li, Guangming; Han, Na; Li, Guotao; Qian, Guowu; Zhang, Shixi; Luo, Hong; Zhang, Donghua; Liang, Hongxia; Ren, Zhigang

doi:10.1186/s12985-025-02771-1

Virology Journal

Table 2 Incidence of adverse events of the study population receiving Azvudine or Paxlovid treatment

From: Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases

Adverse events (N, %)	Available data^a		Grade 1^b			Grade 2^b			Grade ≥ 3^b
Adverse events (N, %)	Azvudine (674)	Paxlovid (364)	Azvudine n (%)	Paxlovid n (%)	P value	Azvudine n (%)	Paxlovid n (%)	P value	Azvudine n (%)	Paxlovid n (%)	P value
ALT increased	423	250	103 (24%)	86 (34%)	0.005	22 (5.2%)	20 (8.0%)	0.15	18 (4.3%)	13 (5.2%)	0.6
AST increased	433	254	78 (18%)	62 (24%)	0.045	20 (4.6%)	10 (3.9%)	0.7	23 (5.3%)	12 (4.7%)	0.7
ALP increased	421	250	39 (9.3%)	24 (9.6%)	0.9	1 (0.2%)	5 (2.0%)	0.029	0 (0%)	1 (0.4%)	0.4
GGT increased	339	242	50 (15%)	48 (20%)	0.11	15 (4.4%)	13 (5.4%)	0.6	3 (0.9%)	7 (2.9%)	0.10
CREA increased	433	247	20 (4.6%)	13 (5.3%)	0.7	24 (5.5%)	12 (4.9%)	0.7	14 (3.2%)	5 (2.0%)	0.4
Hyperuricemia	377	243	42 (11%)	11 (4.5%)	0.004	0	0	NA	0	0	NA
Hypokalemia	467	279	55 (12%)	43 (15%)	0.2	55 (12%)	43 (15%)	0.2	56 (12%)	29 (10%)	0.5
Hyperkalemia	467	279	24 (5.1%)	11 (3.9%)	0.5	23 (4.9%)	11 (3.9%)	0.5	9 (1.9%)	1 (0.4%)	0.10
Hypoglycemia	149	13	38 (26%)	4 (31%)	0.7	0	0	NA	0	0	NA
Hypercholesteremia	107	43	6 (5.6%)	7 (16%)	0.052	1 (0.9%)	0 (0%)	>0.9	0	0	NA
Hypertriglyceridemia	90	40	14 (16%)	10 (25%)	0.2	1 (1.1%)	1 (2.5%)	0.5	1 (1.1%)	0 (0%)	>0.9
Lymphocyte count decreased	570	296	24 (4.2%)	14 (4.7%)	0.7	56 (9.8%)	26 (8.8%)	0.6	153 (27%)	94 (32%)	0.13
Lymphocyte count increased	570	296	6 (1.1%)	4 (1.4%)	0.7	9 (1.6%)	3 (1.0%)	0.8	0 (0%)	2 (0.7%)	0.12
Neutrophil count increased	377	248	6 (1.6%)	4 (1.6%)	>0.9	7 (1.9%)	3 (1.2%)	0.7	7 (1.9%)	3 (1.2%)	0.7
Platelets-count decreased	437	255	26 (5.9%)	18 (7.1%)	0.6	13 (3.0%)	13 (5.1%)	0.2	31 (7.1%)	22 (8.6%)	0.5
Hemoglobin decreased	389	252	66 (17%)	41 (16%)	0.8	41 (11%)	26 (10%)	>0.9	51 (13%)	34 (13%)	0.9

ALT alanine aminotransferase; AST aspartate aminotransferase; ALP alkaline phosphatase; GGT gamma-glutamyl transpeptidase; CREA creatinine
^aNumber of patients who completed the follow-up of data collection for this clinical parameter
^bThe grades of adverse events were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com